TOP-DOWN THERAPY FOR CROHN’S DISEASE : RATIONALE AND EVIDENCE

REFERENCES

• Munkholm P, Langholz E, Davidsen M, Binder V. Disease activitycourses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol 1995;30:699–706.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990;99:956–63.
   PubMed Web of Science ®Google Scholar
• Travis SP, Stange EF, Lemann M, Oresland T, Chowers Y, Forbes A, et al. European evidence based consensus on the diagno-sis and management of Crohn's disease: current management. Gut 2006;55 Suppl 1:i16–35.
   Web of Science ®Google Scholar
• Clark M, Colombel JF, Feagan BC, Fedorak RN, Hanauer SB, Kamm MA, et al. American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. Gastroenterology 2007;133:312–39.
   PubMed Web of Science ®Google Scholar
• Mekhjian HS, Switz DM, Melnyk CS, Rankin GB, Brooks RK. Clin-ical features and natural history of Crohn's disease. Gastroen-terology. 1979;77:898–906.
   PubMed Web of Science ®Google Scholar
• Markowitz J, Grancher K, Kohn N, Lesser M, Daum F. A mul-ticenter trial of 6-mercaptopurine and prednisone in chil-dren with newly diagnosed Crohn's disease. Gastroenterology 2000;119:895–902.
   PubMed Web of Science ®Google Scholar
• Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R. Acontrolled double blind study of azathioprine in the manage-ment of Crohn's disease. Gut 1995;37:674–8.
   PubMed Web of Science ®Google Scholar
• Schreiber et al. Gut 2006;55(Suppl V):A131
   PubMedGoogle Scholar
• Schreiber S, Reinisch W, Colombel JF, Sandborn WJ, Hommes DW, Li J, et al. Early Crohn's Disease Shows High Levels of Re-mission to Therapy With Adalimumab: Sub-analysis of CHARM. Gastroenterology 2007;132(Suppl 2):A147.
   Google Scholar
• D'Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuyn-man H, et al. Early combined immunosuppression or conven-tional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008;371:660–667.
   PubMed Web of Science ®Google Scholar
• Baert F, Moortgat L, Van Assche G, Caenepeel P, Vergauwe P, De Vos M, et al. Mucosal Healing predicts sustained clinical re-mission in early Crohn's disease. Gastroenterology 2008; 134: A–640.
   PubMedGoogle Scholar
• Mucosal T-cell immunoregulation varies in early and late in-flammatory bowel disease. Gut 2007 ;56:1696–705.
   PubMed Web of Science ®Google Scholar
• Froslie KF, Jahnsen J, Moum BA,Vatn MH, Group I. Mucosal heal-ing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007;133:412–22.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Diamond RH, Bala M, et al.: Comparison of sched-uled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004, 126:402–13.
   PubMed Web of Science ®Google Scholar
• Louis E, Vernier-Massouille G, Grimaud J, Bouhnik Y, Laharie D, Dupas J, et al. Infliximab discontinuation in Crohn's disease pa-tients in stable remission on combined therapy with immuno-suppressor: interim analysis of a prospective cohort study. Gut 2008; 57 (supplI1),A66.
   Google Scholar
• Regueiro M, Schraut W, Baidoo L, Kip KE, Sepulveda AR, Pesci M, et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology 2009;136:441–50.
   PubMed Web of Science ®Google Scholar
• Sands, B.E., et al., Infliximab maintenance therapy for fistulizing Crohn's disease. N EngIJ Med, 2004. 350: p.876–85.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Schwartz DA, Sandborn WJ, Kamm M, D'Haens G, Rutgeerts P, et al. Adalimumab for the Treatment of Fistulas in Patients With Crohn's Disease. Gut. 2009 Feb 6. [Epub ahead of print]
   Google Scholar
• Aratari A, Papi C, Leandro G, Viscido A, Capurso L, Caprilli R. Early versus late surgery for ileo-caecal Crohn's disease. ment Pharmacol Ther 2007 ;26:1303–12.
   Web of Science ®Google Scholar
• Kennedy ED, Urbach DR, Krahn MD, Steinhart AH, Cohen Z, McLeod RS. Azathioprine or ileocolic resection for steroid-de-pendent terminal iteat Crohn's disease? A Markov analysis. Dis Colon Rectum 2004;47:2120–30.
   PubMed Web of Science ®Google Scholar
• Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination thera-py with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006 ;54:26–37.
   PubMed Web of Science ®Google Scholar
• Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005 ;52:3381–90.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Rutgeerts P, Reinisch W, Mantzaris GJ Mantzaris, Kornbluth A, et al. SONIC: a randomized, double-blind, con-trolled trial comparing infliximab and infliximab plus azathio-prine to azathioprine in patients naïve to immunomodulators and biologic therapy. Gut 2009;57(Supplement II): A1 Abstract OP001.
   Google Scholar
• Feagan B, McDonald J, Panaccione R, Enns R, Bernstein C, Ponich T, et al. Study to Evaluate the Efficacy of I nfliximab in Com-bination with Methotrexate for the Long-term Treatment of Crohn's Disease. DDW 2008
   Google Scholar
• Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol. 2006 ;4:621–30.
   PubMed Web of Science ®Google Scholar
• Risk factors for opportunistic infections in patients with in-flammatory bowel disease. Toruner M, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn WJ, Colombel JF, Egan Li. Gastroenterology 2008;134:929–36.
   PubMed Web of Science ®Google Scholar
• Beaugerie L, Carrat F, Bouvier AM, Brousse N, Carbonnel F, CotombetFaivre J, et al. Excess risk of lymphoproliferative dis-orders (LPD) in inflammatory bowel diseases: interim results of the Cesa me cohort. Gastroenterology 2008; 134:A–116.
   Google Scholar
• Siegel CA, Hur C, Korzenik J, et al. Risks and benefits of inflix-imab for the treatment of Crohn's disease. Clin Gastroenterol Hepatol 2006; 4: 1017–1024.
   PubMed Web of Science ®Google Scholar
• D'Haens G. Risks and benefits of biologic therapy for inflam-matory bowel diseases. Gut 2007;56:725–32.
   PubMed Web of Science ®Google Scholar
• Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J. Pre-dictors of Crohn's disease. Gastroenterology 2006;130:650–6.
   PubMed Web of Science ®Google Scholar
• Loly C, Belaiche J, Louis E. Predictors of severe Crohn's disease. Scand J Gastroenterol 2008, ;43:948–54.
   PubMed Web of Science ®Google Scholar
• Franchimont DP, Louis E, Croes F, Belaiche J. Clinical pattern of corticosteroid dependent Crohn's disease. Eur Gastroenterol Hepatol 1998;10:821–5.
   PubMed Web of Science ®Google Scholar